Trust Investment Advisors cut its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 13.9% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 27,571 shares of the company’s stock after selling 4,456 shares during the period. Eli Lilly and comprises about 2.7% of Trust Investment Advisors’ portfolio, making the stock its 4th biggest position. Trust Investment Advisors’ holdings in Eli Lilly and were worth $2,358,000 at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. Airain ltd purchased a new stake in Eli Lilly and during the second quarter worth about $567,000. Buckingham Asset Management LLC increased its stake in shares of Eli Lilly and by 21.3% during the second quarter. Buckingham Asset Management LLC now owns 3,232 shares of the company’s stock worth $266,000 after buying an additional 568 shares during the period. BSW Wealth Partners increased its stake in shares of Eli Lilly and by 0.6% during the second quarter. BSW Wealth Partners now owns 4,774 shares of the company’s stock worth $393,000 after buying an additional 27 shares during the period. Sumitomo Life Insurance Co. increased its stake in shares of Eli Lilly and by 4.4% during the second quarter. Sumitomo Life Insurance Co. now owns 32,507 shares of the company’s stock worth $2,675,000 after buying an additional 1,370 shares during the period. Finally, Mirador Capital Partners LP increased its stake in shares of Eli Lilly and by 5.3% during the second quarter. Mirador Capital Partners LP now owns 12,280 shares of the company’s stock worth $1,011,000 after buying an additional 619 shares during the period. Institutional investors own 76.42% of the company’s stock.

A number of analysts recently weighed in on the stock. Morgan Stanley set a $86.00 target price on shares of Eli Lilly and and gave the stock a “hold” rating in a research note on Friday, October 6th. Leerink Swann upped their target price on shares of Eli Lilly and from $92.00 to $93.00 and gave the stock a “market perform” rating in a research note on Monday, October 23rd. BMO Capital Markets set a $73.00 target price on shares of Eli Lilly and and gave the stock a “sell” rating in a research note on Tuesday, October 24th. Credit Suisse Group lowered shares of Eli Lilly and from an “outperform” rating to a “neutral” rating and upped their target price for the stock from $84.23 to $88.00 in a research note on Tuesday, October 10th. Finally, Goldman Sachs Group restated a “buy” rating and set a $95.00 target price (up from $92.00) on shares of Eli Lilly and in a research note on Thursday, October 5th. Three analysts have rated the stock with a sell rating, seven have issued a hold rating and nine have assigned a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus target price of $90.25.

In other news, SVP Alfonso G. Zulueta sold 2,003 shares of the stock in a transaction that occurred on Friday, November 10th. The stock was sold at an average price of $83.67, for a total value of $167,591.01. Following the completion of the sale, the senior vice president now directly owns 43,580 shares of the company’s stock, valued at $3,646,338.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, major shareholder Lilly Endowment Inc sold 195,000 shares of the stock in a transaction that occurred on Friday, September 29th. The shares were sold at an average price of $85.14, for a total value of $16,602,300.00. Following the completion of the sale, the insider now directly owns 123,513,247 shares of the company’s stock, valued at $10,515,917,849.58. The disclosure for this sale can be found here. Insiders sold 651,088 shares of company stock worth $56,439,586 over the last quarter. 0.20% of the stock is currently owned by insiders.

Eli Lilly and Company (LLY) opened at $86.54 on Monday. The company has a market cap of $95,321.79, a P/E ratio of 21.17, a price-to-earnings-growth ratio of 1.76 and a beta of 0.35. Eli Lilly and Company has a one year low of $71.76 and a one year high of $89.09. The company has a quick ratio of 1.03, a current ratio of 1.38 and a debt-to-equity ratio of 0.66.

Eli Lilly and (NYSE:LLY) last announced its quarterly earnings results on Tuesday, October 24th. The company reported $1.05 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.03 by $0.02. The company had revenue of $5.66 billion for the quarter, compared to analyst estimates of $5.52 billion. Eli Lilly and had a net margin of 9.90% and a return on equity of 30.27%. The firm’s revenue was up 9.0% on a year-over-year basis. During the same period in the prior year, the firm posted $0.88 earnings per share. equities research analysts anticipate that Eli Lilly and Company will post 4.22 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Friday, March 9th. Shareholders of record on Thursday, February 15th will be paid a $0.5625 dividend. This is a positive change from Eli Lilly and’s previous quarterly dividend of $0.52. This represents a $2.25 annualized dividend and a yield of 2.60%. The ex-dividend date of this dividend is Wednesday, February 14th. Eli Lilly and’s dividend payout ratio is currently 98.58%.

TRADEMARK VIOLATION WARNING: “Trust Investment Advisors Cuts Holdings in Eli Lilly and Company (LLY)” was originally posted by Watch List News and is owned by of Watch List News. If you are accessing this article on another publication, it was copied illegally and republished in violation of United States & international trademark & copyright laws. The legal version of this article can be read at https://www.watchlistnews.com/trust-investment-advisors-cuts-holdings-in-eli-lilly-and-company-lly/1771212.html.

Eli Lilly and Profile

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.